MagForce to implement capital increase of up to €33.5 million

2013-02-08 13:08:14 -
MagForce AG  /
MagForce to implement capital increase of up to €33.5 million
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement. 

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN, OR AUSTRALIA

  * Capital increase against cash and noncash contributions including preemptive
    rights
  * Funds to go towards post-marketing study and loan repayment
  * BaFin approves securities prospectus


Berlin,  Germany,  February  08, 2013 -  MagForce  AG (Frankfurt, XETRA: MF6), a
leading  medical technology  company in  the field  of nanomedicine in oncology,
intends  to implement a capital increase  against cash and noncash contributions
including  preemptive rights  in the 
  
    
      
        

	    
  
   total amount  of around  €33.5 million. To
achieve  this, up to  18,606,553 new no-par value  bearer shares will be issued.
The  capitalization measure was resolved  at the Company's extraordinary general
meeting on January 25, 2013.

Bankhaus  Neelmeyer  AG,  Bremen,  will  offer  the  new shares to the Company's
shareholders for sub-scription at a ratio of 2:7. The subscription price for the
new  shares will  be €1.80  per share.  The two-week  shareholders' subscription
period  will run from February  14 to February 28, 2013. Clearstream Banking AG,
Frankfurt  am Main, will settle  the rights for the  new shares. The rights will
not be traded on the stock exchange.

Further  details are  provided in  the securities  prospectus, which the company
filed  with  the  commercial  register  today.  In line with legal requirements,
Bundesanstalt  für Finanzdienstleistungsaufsicht  (BaFin -  the German Financial
Supervisory  Authority) examined and approved the  prospectus. It is expected to
be  published in the Bundesanzeiger  (Federal Gazette) on February 14, 2013. The
prospectus  is available on  the Company's website  at www.magforce.de under the
section entitled "Press and Investors" (German only).

In the short to medium term, MagForce will use part of these cash funds achieved
in  the transaction to finance the  post-marketing glioblastoma study as well as
business  operations. In addition, the Company will repay loans in the amount of
€16.1  million to its primary creditors, insofar as this amount is not converted
to equity as part of a debt-to-equity swap.


About MagForce AG

MagForce AG is a leading medical technology company in the field of nanomedicine
in oncology. The Company's proprietary, NanoTherm® therapy, enables the targeted
treatment  of  solid  tumors  through  the  intratumoral  generation of heat via
activation    of    magnetic    nanoparticles.    NanoTherm®,   NanoPlan®,   and
NanoActivator(TM)  are  components  of  the  therapy  and  have received EU-wide
regulatory  approval  as  medical  devices  for  the  treatment of brain tumors.
MagForce,   NanoTherm®,  NanoPlan®,  and  NanoActivator(TM)  are  trademarks  of
MagForce   AG   in   select   countries.  For  more  information,  please  visit
www.magforce.com.



Disclaimer

This release may contain forward-looking statements and information which may be
identified by formulations using terms such as "expects", "aims",
"anticipates",
"intends",  "plans", "believes",  "seeks",
"estimates"  or "will". Such forward-
looking   statements   are   based  on  our  current  expectations  and  certain
assumptions,  which may be subject to a  variety of risks and uncertainties. The
results  actually achieved  by MagForce  AG may  substantially differ from these
forward-looking  statements. MagForce AG  assumes no obligation  to update these
forward-looking  statements or  to correct  them in  case of developments, which
differ from those, anticipated.


Contact:

Anne Hennecke
MC Services AG

T +49 89 210228-18
F +49 89 210228-88
M +49 151 12 555 759

Email: anne.hennecke@mc-services.eu



MagForce_Press Release_Feb 08, 2013: 
 hugin.info/143761/R/1676740/546608.pdf



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: MagForce AG  via Thomson Reuters ONE
[HUG#1676740]